Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 220

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Mass spectrometry-based proteomics as an emerging tool in clinical laboratories

Open access
Birhanu, Alemayehu Godana · 2023 · Clinical Proteomics

Abstract

Mass spectrometry (MS)-based proteomics have been increasingly implemented in various disciplines of laboratory medicine to identify and quantify biomolecules in a variety of biological specimens. MS-based proteomics is continuously expanding and widely applied in biomarker discovery for early detection, prognosis and markers for treatment response prediction and monitoring. Furthermore, making these advanced tests more accessible and affordable will have the greatest healthcare benefit. This review article highlights the new paradigms MS-based clinical proteomics has created in microbiology laboratories, cancer research and diagnosis of metabolic disorders. The technique is preferred over conventional methods in disease detection and therapy monitoring for its combined advantages in multiplexing capacity, remarkable analytical specificity and sensitivity and low turnaround time. Despite the achievements in the development and adoption of a number of MS-based clinical proteomics practices, more are expected to undergo transition from bench to bedside in the near future. The review provides insights from early trials and recent progresses (mainly covering literature from the NCBI database) in the application of proteomics in clinical laboratories.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12014-023-09424-x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 306

  1. Jimenez CR, Verheul HM. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications. Am Soc Clin Oncol Educational Book. 2014;34(1):e504–10. · DOI
  2. Sevimoglu T, Arga KY. The role of protein interaction networks in systems biomedicine. Comput Struct Biotechnol J. 2014;11(18):22–7. · DOI
  3. Gonzalez MW, Kann MG. Chap. 4: Protein interactions and disease PLoS computational biology, 2012. 8(12): p. e1002819. · DOI · Paper page
  4. Khodadadi E, et al. Proteomic applications in antimicrobial resistance and clinical microbiology studies. Infect Drug Resist. 2020;13:1785. · DOI
  5. Iwamoto N, Shimada T. Recent advances in mass spectrometry-based approaches for proteomics and biologics: great contribution for developing therapeutic antibodies. Volume 185. Pharmacology & Therapeutics; 2018. pp. 147–54. · DOI
  6. Clarke NJ, Zhang Y, Reitz RE. A novel mass spectrometry–based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies. J Investig Med. 2012;60(8):1157–63. · DOI
  7. Rostaing L, et al. Falsely elevated whole-blood tacrolimus concentrations in a kidney‐transplant patient: potential hazards. Transpl Int. 2010;23(2):227–30. · doi:10.1111/j.1432-2277.2009.00965.x
  8. Hanash S. Disease proteomics. Nature. 2003;422(6928):226–32. · DOI · Paper page
  9. Oliveira BM, et al. Is clinical proteomics heading towards to “bench to bedside. Transl Proteom. 2013;1(1):53–6.
  10. Mischak H. How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS. PROTEOMICS–Clinical Appl. 2012;6(9–10):437–42. · DOI
  11. Mischak H, et al. Implementation of proteomic biomarkers: making it work. Eur J Clin Invest. 2012;42(9):1027–36. · DOI · Paper page
  12. Baker ES, et al. Mass spectrometry for translational proteomics: progress and clinical implications. Genome Med. 2012;4(8):1–11. · DOI
  13. Boja ES, Rodriguez H. The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science. Korean J Lab Med. 2011;31(2):61–71.
  14. Maes E, et al. Proteomics in cancer research: are we ready for clinical practice? Crit Rev Oncol/Hematol. 2015;96(3):437–48. · DOI
  15. Findeisen P, Neumaier M. Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev Proteomics. 2009;6(5):457–9. · DOI
  16. Lill JR, et al. Proteomics in the pharmaceutical and biotechnology industry: a look to the next decade. Expert Rev Proteomics. 2021;18(7):503–26. · DOI
  17. Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation–quality assurance and control of protein biomarker assays. Mol Oncol. 2014;8(4):840–58. · DOI · Paper page
  18. Srinivas PR, et al. Proteomics for cancer biomarker discovery. Clin Chem. 2002;48(8):1160–9.
  19. Olsson B, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84. · DOI · Paper page
  20. Jang HN et al. Mass Spectrometry-Based Proteomic Discovery of prognostic biomarkers in adrenal cortical carcinoma. Cancers (Basel), 2021. 13(15). · DOI
  21. Gam L-H. Breast cancer and protein biomarkers. World J experimental Med. 2012;2(5):86.
  22. Hamdan MH. Cancer biomarkers: analytical techniques for discovery. John Wiley & Sons; 2007. · doi:10.1002/047011312x
  23. Amiri-Dashatan N, et al. Proteomics applications in health: biomarker and drug discovery and food industry. Iran J Pharm research: IJPR. 2018;17(4):1523.
  24. Yang WS, et al. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. J Proteome Res. 2012;11(2):1078–88. · DOI
  25. Zhang D, Putti TC. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells. Exp Cell Res. 2010;316(20):3522–31. · DOI
  26. Banerjee S. Empowering clinical diagnostics with mass spectrometry. ACS omega. 2020;5(5):2041–8. · DOI
  27. Blattmann P, Aebersold R. The Advent of Mass Spectrometry-Based Proteomics in Systems Biology Research 2016. · DOI
  28. Macklin A, Khan S, Kislinger T. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clin Proteom. 2020;17(1):17. · DOI · Paper page
  29. Lange V, et al. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol. 2008;4(1):222. · DOI · Paper page
  30. Wu W, Dai R-T, Bendixen E. Comparing SRM and SWATH methods for quantitation of bovine muscle proteomes. J Agric Food Chem. 2019;67(5):1608–18. · DOI
  31. Mermelekas G, Vlahou A, Zoidakis J. SRM/MRM targeted proteomics as a tool for biomarker validation and absolute quantification in human urine. Expert Rev Mol Diagn. 2015;15(11):1441–54. · DOI
  32. Jones JJ, et al. A plasma-based protein marker panel for Colorectal Cancer Detection identified by Multiplex targeted Mass Spectrometry. Clin Colorectal Cancer. 2016;15(2):186–194e13. · DOI
  33. Kontostathi G, et al. Applications of multiple reaction monitoring targeted proteomics assays in human plasma. Expert Rev Mol Diagn. 2019;19(6):499–515. · DOI
  34. Boys EL, et al. Clinical applications of mass spectrometry-based proteomics in cancer: where are we? Proteomics. 2023;23(7–8):e2200238. · DOI
  35. Ludwig C, et al. Data-independent acquisition‐based SWATH‐MS for quantitative proteomics: a tutorial. Mol Syst Biol. 2018;14(8):e8126. · DOI · Paper page
  36. Tully B, et al. Addressing the challenges of high-throughput cancer tissue proteomics for clinical application: proCan. Proteomics. 2019;19(21–22):1900109. · DOI
  37. Poulos RC, et al. Strategies to enable large-scale proteomics for reproducible research. Nat Commun. 2020;11(1):1–13. · DOI
  38. Reubsaet L, Sweredoski MJ, Moradian A. Data-independent acquisition for the Orbitrap Q Exactive HF: a tutorial. J Proteome Res. 2018;18(3):803–13. · DOI
  39. Chang RY, et al. SWATH analysis of the synaptic proteome in Alzheimer’s disease. Neurochem Int. 2015;87:1–12. · DOI
  40. Kim YJ, et al. Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies. J Proteom. 2018;189:91–6. · DOI
  41. Anjo SI, Santa C, Manadas B. SWATH-MS as a tool for biomarker discovery: from basic research to clinical applications. Proteomics. 2017;17:3–4.
  42. de Wit M, et al. Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem. 2013;46(6):466–79. · DOI
  43. Patterson SD, Aebersold RH. Proteomics: the first decade and beyond. Nat Genet. 2003;33(3):311–23. · DOI · Paper page
  44. Fung AW, et al. Emerging role of clinical mass spectrometry in pathology. J Clin Pathol. 2020;73(2):61–9. · DOI
  45. Satoh M, Nomura F. Applications of mass spectrometry in clinical chemistry. Med Mass Spectrom. 2019;3(1):2–10.
  46. Stone J. Sample preparation techniques for mass spectrometry in the clinical laboratory, Mass Spectrometry for the Clinical Laboratory. 2017, Elsevier. 37–62. · DOI
  47. Principe S, et al. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res. 2012;11(4):2386–96. · DOI
  48. Drake RR, et al. In-depth proteomic analyses of direct expressed prostatic secretions. J Proteome Res. 2010;9(5):2109–16. · DOI
  49. Wu CC, et al. Saliva proteome profiling reveals potential salivary biomarkers for detection of oral cavity squamous cell carcinoma. Proteomics. 2015;15(19):3394–404. · DOI
  50. de Souza GA, de Godoy LM, Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol. 2006;7(8):1–11. · DOI · Paper page
  51. Spreafico F, et al. Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget. 2017;8(28):46177. · DOI
  52. Elschenbroich S, et al. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res. 2011;10(5):2286–99. · DOI
  53. Gortzak-Uzan L, et al. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res. 2008;7(01):339–51. · DOI · Paper page
  54. Ding Z, et al. Proteomics technologies for cancer liquid biopsies. Mol Cancer. 2022;21(1):1–11. · DOI · Paper page
  55. Anderson NL, et al. Mass spectrometric quantitation of peptides and proteins using stable isotope Standards and capture by Anti-Peptide antibodies (SISCAPA). J Proteome Res. 2004;3(2):235–44. · DOI · Paper page
  56. Denti V, et al. Antigen Retrieval and its effect on the MALDI-MSI of lipids in Formalin-Fixed paraffin-embedded tissue. J Am Soc Mass Spectrom. 2020;31(8):1619–24. · doi:10.1021/jasms.0c00208
  57. Ly A, et al. High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. Nat Protoc. 2016;11(8):1428–43. · DOI · Paper page
  58. Eckert MA, et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019;569(7758):723–8. · DOI · Paper page
  59. Sinha A, et al. The proteogenomic landscape of curable prostate cancer. Cancer Cell. 2019;35(3):414–27. e6. · DOI · Paper page
  60. Wang H, et al. Development and evaluation of a micro-and nanoscale proteomic sample preparation method. J Proteome Res. 2005;4(6):2397–403. · DOI · Paper page
  61. Frantzi M, et al. Development and validation of urine-based peptide biomarker panels for detecting bladder Cancer in a multi-center StudyDevelopment of urinary biomarker panels for bladder Cancer. Clin Cancer Res. 2016;22(16):4077–86. · DOI
  62. Lee H-J, Kim H-J, Liebler DC. Efficient microscale basic reverse phase peptide fractionation for global and targeted proteomics. J Proteome Res. 2016;15(7):2346–54. · DOI
  63. Cooper HJ. To what extent is FAIMS beneficial in the analysis of proteins? J Am Soc Mass Spectrom. 2016;27(4):566–77. · DOI
  64. Michelmann K, et al. Fundamentals of trapped ion mobility spectrometry. J Am Soc Mass Spectrom. 2014;26(1):14–24. · DOI · Paper page
  65. Hebert AS, et al. Comprehensive single-shot proteomics with FAIMS on a hybrid orbitrap mass spectrometer. Anal Chem. 2018;90(15):9529–37. · DOI · Paper page
  66. Manza LL, et al. Sample preparation and digestion for proteomic analyses using spin filters. Proteomics. 2005;5(7):1742–5. · DOI · Paper page
  67. Berger ST, et al. MStern blotting–high throughput polyvinylidene fluoride (PVDF) membrane-based Proteomic Sample Preparation for 96-Well Plates*[S]. Volume 14. Molecular & Cellular Proteomics; 2015. pp. 2814–23. 10. · DOI
  68. Zougman A, Selby PJ, Banks RE. Suspension trapping (STrap) sample preparation method for bottom-up proteomics analysis. Proteomics. 2014;14(9):1006–1000. · DOI · Paper page
  69. HaileMariam M, et al. S-Trap, an ultrafast sample-preparation approach for shotgun proteomics. J Proteome Res. 2018;17(9):2917–24. · DOI · Paper page
  70. Hughes CS, et al. Ultrasensitive proteome analysis using paramagnetic bead technology. Mol Syst Biol. 2014;10(10):757. · DOI · Paper page
  71. Leutert M, et al. R2-P2 rapid‐robotic phosphoproteomics enables multidimensional cell signaling studies. Mol Syst Biol. 2019;15(12):e9021. · DOI · Paper page
  72. Hughes CS, et al. Quantitative profiling of single formalin fixed tumour sections: proteomics for translational research. Sci Rep. 2016;6(1):1–14. · DOI · Paper page
  73. Owen DR, et al. Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Mol Case Stud. 2018;4(2):a002535. · DOI
  74. Ludwig KR, Schroll MM, Hummon AB. Comparison of in-solution, FASP, and S-trap based digestion methods for bottom-up proteomic studies. J Proteome Res. 2018;17(7):2480–90. · DOI · Paper page
  75. Sielaff M, et al. Evaluation of FASP, SP3, and iST protocols for proteomic sample preparation in the low microgram range. J Proteome Res. 2017;16(11):4060–72. · DOI · Paper page
  76. Hughes CS, et al. Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc. 2019;14(1):68–85. · DOI · Paper page
  77. Li C et al. Towards higher sensitivity of mass spectrometry: a perspective from the mass analyzers. Front Chem, 2021. 9. · DOI
  78. Andrews GL, et al. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Anal Chem. 2011;83(13):5442–6. · DOI · Paper page
  79. Schilling B, et al. Multiplexed, scheduled, high-resolution parallel reaction monitoring on a full scan QqTOF instrument with integrated data-dependent and targeted mass spectrometric workflows. Anal Chem. 2015;87(20):10222–9. · DOI
  80. Nyadong L, et al. Laserspray and matrix-assisted ionization inlet coupled to high-field FT-ICR mass spectrometry for peptide and protein analysis. J Am Soc Mass Spectrom. 2013;24(3):320–8. · DOI
  81. Jarmusch AK, et al. Lipid and metabolite profiles of human brain tumors by desorption electrospray ionization-MS. Proc Natl Acad Sci. 2016;113(6):1486–91. · DOI · Paper page
  82. Yoshimura K, et al. Development of non-proximate probe electrospray ionization for real-time analysis of living animal. Mass Spectrom. 2015;3(SpecialIssue3):S0048–8. · doi:10.5702/massspectrometry.s0048
  83. St John ER, et al. Rapid evaporative ionisation mass spectrometry of electrosurgical vapours for the identification of breast pathology: towards an intelligent knife for breast cancer surgery. Breast Cancer Res. 2017;19(1):1–14. · DOI · Paper page
  84. Sinitcyn P, et al. MaxDIA enables library-based and library-free data-independent acquisition proteomics. Nat Biotechnol. 2021;39(12):1563–73. · DOI · Paper page
  85. Taunk K, et al. The development and clinical applications of proteomics: an indian perspective. Expert Rev Proteomics. 2020;17(6):433–51. · DOI
  86. Chong Y-K, et al. Clinical mass spectrometry in the bioinformatics era: a Hitchhiker’s guide. Comput Struct Biotechnol J. 2018;16:316–34. · DOI
  87. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol. 2005;563(Pt 1):23–60. · DOI · Paper page
  88. Paulovich AG, et al. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteom Clin Appl. 2008;2(10–11):1386–402. · DOI · Paper page
  89. Whiteaker JR, et al. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res. 2007;6(10):3962–75. · DOI · Paper page
  90. Kiyonami R et al. Increased selectivity, analytical precision, and throughput in targeted proteomics. Mol Cell Proteomics, 2011. 10(2): p. M110.002931. · DOI · Paper page
  91. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56(2):177–85. · DOI · Paper page
  92. van der Gugten JG. Tandem mass spectrometry in the clinical laboratory: a tutorial overview. Clin Mass Spectrom. 2020;15:36–43. · DOI
  93. DeMarco ML, et al. An automated clinical mass spectrometric method for identification and quantification of variant and wild-type amyloid-β 1–40 and 1–42 peptides in CSF. Alzheimers Dement (Amst). 2020;12(1):e12036.
  94. Chambers AG, et al. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev Proteomics. 2014;11(2):137–48. · DOI
  95. Foster AG. Rapid identification of microbes in positive blood cultures by use of the Vitek MS matrix-assisted laser desorption ionization–time of flight mass spectrometry system. J Clin Microbiol. 2013;51(11):3717–9. · DOI
  96. Faron ML, et al. Multicenter evaluation of the Bruker MALDI Biotyper CA System for the identification of clinical aerobic gram-negative bacterial isolates. PLoS ONE. 2015;10(11):e0141350. · doi:10.1371/journal.pone.0141350
  97. Frank KM. Microbiology in Clinical Pathology, in Pathobiology of Human Disease. San Diego: Academic Press; 2014. pp. 3237–68. L.M. McManus and R.N. Mitchell, Editors. · DOI
  98. Nolen BM, Lokshin AE. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther. 2013;17(3):139–46. · DOI
  99. Boja ES, et al. Analytical Validation Considerations of Multiplex Mass-Spectrometry-Based proteomic platforms for measuring protein biomarkers. J Proteome Res. 2014;13(12):5325–32. · DOI
  100. Clarke W, Rhea JM, Molinaro R. Challenges in implementing clinical liquid chromatography-tandem mass spectrometry methods–the light at the end of the tunnel. J Mass Spectrom. 2013;48(7):755–67. · DOI
  101. Turck CW, et al. The association of biomolecular resource facilities proteomics research group 2006 study: relative protein quantitation. Mol Cell Proteom. 2007;6(8):1291–8. · DOI
  102. Kim SR, et al. Comparative proteomics: assessment of biological variability and dataset comparability. BMC Bioinformatics. 2015;16(1):1–10. · DOI · Paper page
  103. Bag AK, et al. Comparative proteomics and glycoproteomics of plasma proteins in indian visceral leishmaniasis. Proteome Sci. 2014;12(1):1–15. · DOI
  104. Minden J. Comparative proteomics and difference gel electrophoresis. Biotechniques. 2007;43(6):739–45. · DOI
  105. Volmer DA, Mendes LR, Stokes CS. Analysis of vitamin D metabolic markers by mass spectrometry: current techniques, limitations of the “gold standard” method, and anticipated future directions. Mass Spectrom Rev. 2015;34(1):2–23. · DOI
  106. Nguyen CDL, et al. A sensitive and simple targeted proteomics approach to quantify transcription factor and membrane proteins of the unfolded protein response pathway in glioblastoma cells. Sci Rep. 2019;9(1):8836. · DOI
  107. Ronsein GE, et al. Parallel reaction monitoring (PRM) and selected reaction monitoring (SRM) exhibit comparable linearity, dynamic range and precision for targeted quantitative HDL proteomics. J Proteom. 2015;113:388–99. · DOI · Paper page
  108. Zhou X, Zhang W, Ouyang Z. Recent advances in on-site mass spectrometry analysis for clinical applications. TRAC Trends Anal Chem, 2022: p. 116548. · DOI
  109. Chamberlain CA, Rubio VY, Garrett TJ. Strain-level differentiation of Bacteria by Paper Spray Ionization Mass Spectrometry. Anal Chem. 2019;91(8):4964–8. · DOI
  110. Longuespée R, et al. MALDI mass spectrometry imaging: a cutting-edge tool for fundamental and clinical histopathology. PROTEOMICS–Clinical Appl. 2016;10(7):701–19. · DOI
  111. Kriegsmann J, Kriegsmann M, Casadonte R. MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics. Int J Oncol. 2015;46(3):893–906. · DOI · Paper page
  112. Jannetto PJ, Fitzgerald RL. Effective use of mass spectrometry in the clinical laboratory. Clin Chem. 2016;62(1):92–8. · DOI · Paper page
  113. Buchberger AR, et al. Mass spectrometry imaging: a review of emerging advancements and future insights. Anal Chem. 2018;90(1):240. · DOI · Paper page
  114. Banerjee S. Ambient ionization mass spectrometry imaging for disease diagnosis: excitements and challenges. J Biosci. 2018;43(4):731–8. · DOI
  115. Eberlin LS et al. Desorption electrospray ionization mass spectrometry for lipid characterization and biological tissue imaging Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 2011. 1811(11): p. 946–60. · DOI · Paper page
  116. Barry JA, et al. Mapping antiretroviral drugs in tissue by IR-MALDESI MSI coupled to the Q exactive and comparison with LC-MS/MS SRM assay. J Am Soc Mass Spectrom. 2014;25(12):2038–47. · DOI
  117. Yang H, et al. Mass Spectrometry Imaging of Microbes. Mass Spectrom Lett. 2020;11(3):41–51.
  118. Arentz G, et al. Applications of mass spectrometry imaging to cancer. Adv Cancer Res. 2017;134:27–66. · DOI
  119. Ucal Y, et al. Clinical applications of MALDI imaging technologies in cancer and neurodegenerative diseases. Biochim et Biophys Acta (BBA)-Proteins Proteom. 2017;1865(7):795–816. · DOI
  120. Eberlin LS, et al. Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. Angew Chem. 2010;122(34):6089–92. · doi:10.1002/ange.201001452
  121. Ifa DR, Eberlin LS. Ambient ionization mass spectrometry for cancer diagnosis and surgical margin evaluation. Clin Chem. 2016;62(1):111–23. · DOI · Paper page
  122. Banerjee S, Manna SK. Assessment of metabolic signature for Cancer diagnosis using Desorption Electrospray Ionization Mass Spectrometric Imaging, Cancer Metabolism. 2019, Springer. 275–97. · DOI
  123. Holzlechner M, Eugenin E, Prideaux B. Mass spectrometry imaging to detect lipid biomarkers and disease signatures in cancer. Cancer Rep. 2019;2(6):e1229. · DOI
  124. Kriegsmann J, et al. Mass spectrometry in pathology–vision for a future workflow. Pathology-Research and Practice. 2018;214(8):1057–63. · DOI
  125. Diehl HC, et al. The challenge of on-tissue digestion for MALDI MSI—a comparison of different protocols to improve imaging experiments. Anal Bioanal Chem. 2015;407(8):2223–43. · DOI
  126. Hermann J, et al. Sample preparation of formalin-fixed paraffin-embedded tissue sections for MALDI-mass spectrometry imaging. Anal Bioanal Chem. 2020;412(6):1263–75. · doi:10.1007/s00216-019-02296-x
  127. Leung F, et al. Mass spectrometry-based tissue imaging: the next frontier in clinical diagnostics? Clin Chem. 2019;65(4):510–3. · doi:10.1373/clinchem.2018.289694
  128. Perez CJ, et al. Review and perspectives on the applications of mass spectrometry imaging under ambient conditions. Rapid Commun Mass Spectrom. 2019;33:27–53. · DOI
  129. Schäfer KC, et al. In vivo, in situ tissue analysis using rapid evaporative ionization mass spectrometry. Angew Chem Int Ed. 2009;48(44):8240–2. · DOI · Paper page
  130. Golf O, et al. Rapid evaporative ionization mass spectrometry imaging platform for direct mapping from bulk tissue and bacterial growth media. Anal Chem. 2015;87(5):2527–34. · DOI
  131. Balog J, et al. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med. 2013;5(194):194ra93–3. · DOI · Paper page
  132. Balog J, et al. Identification of biological tissues by rapid evaporative ionization mass spectrometry. Anal Chem. 2010;82(17):7343–50. · DOI · Paper page
  133. Alexander J, et al. A novel methodology for in vivo endoscopic phenotyping of colorectal cancer based on real-time analysis of the mucosal lipidome: a prospective observational study of the iKnife. Surg Endosc. 2017;31(3):1361–70. · DOI
  134. Greco TM, Cristea IM. Proteomics tracing the footsteps of infectious disease. Mol Cell Proteom. 2017;16(4):S5–S14. · DOI
  135. Wu F, Zhong F, He F. Microbial proteomics: approaches, advances, and applications. J Bioinf Proteom Imaging Anal. 2016;2(1):85–91.
  136. Jean Beltran PM, et al. Proteomics and integrative omic approaches for understanding host–pathogen interactions and infectious diseases. Mol Syst Biol. 2017;13(3):922. · DOI · Paper page
  137. Singhal N, et al. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:791. · DOI · Paper page
  138. Sauer S, Kliem M. Mass spectrometry tools for the classification and identification of bacteria. Nat Rev Microbiol. 2010;8(1):74–82. · DOI · Paper page
  139. Welker M, Moore ER. Applications of whole-cell matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry in systematic microbiology. Syst Appl Microbiol. 2011;34(1):2–11. · DOI · Paper page
  140. Idelevich EA, Becker K. Matrix-assisted laser desorption ionization–time of Flight Mass Spectrometry for Antimicrobial susceptibility testing. J Clin Microbiol. 2021;59(12):e01814–19. · DOI
  141. Clark AE, et al. Matrix-assisted laser desorption ionization–time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin Microbiol Rev. 2013;26(3):547–603. · DOI · Paper page
  142. Lee C-R, et al. Quantitative proteomic view associated with resistance to clinically important antibiotics in Gram-positive bacteria: a systematic review. Front Microbiol. 2015;6:828.
  143. Stekhoven DJ, et al. Proteome-wide identification of predominant subcellular protein localizations in a bacterial model organism. J Proteom. 2014;99:123–37. · DOI
  144. Sperk M, et al. Utility of proteomics in emerging and re-emerging infectious diseases caused by RNA viruses. J Proteome Res. 2020;19(11):4259–74. · DOI
  145. Havlicek V, Lemr K, Schug KA. Current trends in microbial diagnostics based on mass spectrometry. Anal Chem. 2013;85(2):790–7. · DOI
  146. Seng P, et al. MALDI-TOF-mass spectrometry applications in clinical microbiology. Future Microbiol. 2010;5(11):1733–54. · DOI · Paper page
  147. Holland R, et al. Rapid identification of intact whole bacteria based on spectral patterns using matrix-assisted laser desorption/ionization with time‐of‐flight mass spectrometry. Rapid Commun Mass Spectrom. 1996;10(10):1227–32. · DOI · Paper page
  148. Cox CR, Voorhees KJ. Bacterial identification by Mass Spectrometry, Detection of Chemical, Biological, Radiological and Nuclear Agents for the Prevention of Terrorism. 2014, Springer. 115–31. · doi:10.1007/978-94-017-9238-7_8
  149. Bizzini A, et al. Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of bacterial strains routinely isolated in a clinical microbiology laboratory. J Clin Microbiol. 2010;48(5):1549–54. · DOI · Paper page
  150. Steensels D, Verhaegen J, Lagrou K. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of bacteria and yeasts in a clinical microbiological laboratory: a review. Acta Clin Belg. 2011;66(4):267–73.
  151. Berendsen EM, et al. Identification of microorganisms grown in blood culture flasks using liquid chromatography–tandem mass spectrometry. Future Microbiol. 2017;12(13):1135–45. · DOI
  152. Lasch P, et al. Identification of microorganisms by liquid chromatography-mass spectrometry (LC-MS1) and in silico peptide mass libraries. Mol Cell Proteom. 2020;19(12):2125–39. · DOI
  153. Kostrzewa M. Application of the MALDI biotyper to clinical microbiology: progress and potential. Expert Rev Proteomics. 2018;15(3):193–202. · DOI
  154. Bahk YY, et al. Antigens secreted from Mycobacterium tuberculosis: identification by proteomics approach and test for diagnostic marker. Proteomics. 2004;4(11):3299–307. · DOI
  155. La Scola B, Raoult D. Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. PLoS ONE. 2009;4(11):e8041. · DOI · Paper page
  156. Stevenson LG, Drake SK, Murray PR. Rapid identification of bacteria in positive blood culture broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2010;48(2):444–7. · DOI · Paper page
  157. Haigh J, et al. Rapid identification of bacteria from bioMerieux BacT/ALERT blood culture bottles by MALDI-TOF MS. Br J Biomed Sci. 2013;70(4):149–55. · doi:10.1080/09674845.2013.11669949
  158. Tadros M, Petrich A. Evaluation of MALDI-TOF mass spectrometry and Sepsityper Kit™ for the direct identification of organisms from sterile body fluids in a canadian pediatric hospital. Can J Infect Dis Med Microbiol. 2013;24(4):191–4. · DOI
  159. Nomura F, et al. Mass spectrometry-based microbiological testing for blood stream infection. Clin Proteomics. 2020;17(1):1–11. · DOI
  160. Guembe M et al. Can MALDI-TOF mass spectrometry be used with intravascular catheters? Enfermedades Infecciosas y Microbiología Clínica, 2014. 32(6): p. 372–4. · doi:10.1016/j.eimc.2014.01.011
  161. Roux-Dalvai F, et al. Fast and accurate bacterial species identification in urine specimens using LC-MS/MS Mass Spectrometry and Machine Learning*[S]. Volume 18. Molecular & Cellular Proteomics; 2019. pp. 2492–505. 12. · DOI
  162. Kitagawa K, et al. Improved bacterial identification directly from urine samples with matrix-assisted laser desorption/ionization time‐of‐flight mass spectrometry. J Clin Lab Anal. 2018;32(3):e22301. · doi:10.1002/jcla.22301
  163. Ferreira L, et al. Direct identification of urinary tract pathogens from urine samples by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2010;48(6):2110–5. · DOI · Paper page
  164. Köhling HL, et al. Direct identification of bacteria in urine samples by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and relevance of defensins as interfering factors. J Med Microbiol. 2012;61(3):339–44. · DOI
  165. Burillo A, et al. Gram-stain plus MALDI-TOF MS (matrix-assisted laser desorption ionization-time of flight mass spectrometry) for a rapid diagnosis of urinary tract infection. PLoS ONE. 2014;9(1):e86915. · DOI
  166. El-Sadek WAE-L. Matrix-assisted laser desorption ionization-time of Flight Mass Spectrometry (MALDI-TOF MS) for the identification of Bacteria causing urinary tract infections. Egypt J Med Microbiol. 2021;30(4):103–12. · doi:10.21608/ejmm.2021.197468
  167. Pinault L, et al. Direct identification of pathogens in urine by use of a specific matrix-assisted laser desorption ionization–time of flight spectrum database. J Clin Microbiol. 2019;57(4):e01678–18. · DOI
  168. He Y, et al. Mass spectrometry biotyper system identifies enteric bacterial pathogens directly from colonies grown on selective stool culture media. J Clin Microbiol. 2010;48(11):3888–92. · DOI
  169. Dierig A, Frei R, Egli A. The fast route to microbe identification: matrix assisted laser desorption/ionization—time of flight mass spectrometry (MALDI-TOF MS) The Pediatric infectious disease journal, 2015. 34(1): p. 97–9. · doi:10.1097/inf.0000000000000601
  170. Segawa S, et al. Direct application of MALDI-TOF mass spectrometry to cerebrospinal fluid for rapid pathogen identification in a patient with bacterial meningitis. Clin Chim Acta. 2014;435:59–61. · DOI
  171. Tsuchida S, Umemura H, Nakayama T. Current status of matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS) in clinical diagnostic microbiology. Molecules. 2020;25(20):4775. · DOI · Paper page
  172. Bishop B, et al. The use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for rapid bacterial identification in patients with smear-positive bacterial meningitis. Clin Microbiol Infect. 2018;24(2):171–4. · DOI
  173. Luo Y, et al. Performance of the VITEK MS matrix-assisted laser desorption ionization-time of flight mass spectrometry system for rapid bacterial identification in two diagnostic centres in China. J Med Microbiol. 2015;64(1):18–24. · DOI
  174. Pecora N, Milner DA Jr. New Technologies for the diagnosis of infection. Diagnostic Pathology of Infectious Disease; 2018. pp. 104–17. · DOI
  175. Patel R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin Chem. 2015;61(1):100–11. · DOI · Paper page
  176. Yoon E-J, Jeong SH. MALDI-TOF mass spectrometry technology as a tool for the rapid diagnosis of antimicrobial resistance in bacteria. Antibiotics. 2021;10(8):982. · DOI
  177. Florio W, et al. Detection of antibiotic-resistance by MALDI-TOF mass spectrometry: an expanding area. Front Cell Infect Microbiol. 2020;10:572909. · DOI
  178. Aleshukina A, et al. Mass spectrometric study of antibiotic resistance of S. aureus and P. aeruginosa using the MALDIquant package. Int J Infect Dis. 2022;116:S12. · doi:10.1016/j.ijid.2021.12.028
  179. Weis C, et al. Direct antimicrobial resistance prediction from clinical MALDI-TOF mass spectra using machine learning. Nat Med. 2022;28(1):164–74. · DOI · Paper page
  180. Charretier Y, Schrenzel J. Mass spectrometry methods for predicting antibiotic resistance. PROTEOMICS–Clinical Appl. 2016;10(9–10):964–81. · DOI
  181. Kliem M, Sauer S. The essence on mass spectrometry based microbial diagnostics. Curr Opin Microbiol. 2012;15(3):397–402. · DOI
  182. Sjöholm MI, Dillner J, Carlson J. Multiplex detection of human herpesviruses from archival specimens by using matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2008;46(2):540–5. · DOI
  183. Yi X, et al. A new PCR-based mass spectrometry system for high-risk HPV, part I: methods. Am J Clin Pathol. 2011;136(6):913–9. · DOI
  184. Du H, et al. A new PCR-based mass spectrometry system for high-risk HPV, part II: clinical trial. Am J Clin Pathol. 2011;136(6):920–3. · DOI
  185. Piao J et al. Simultaneous detection and identification of enteric viruses by PCR-mass assay 2012. · DOI
  186. Downard KM, Morrissey B, Schwahn AB. Mass spectrometry analysis of the influenza virus. Mass Spectrom Rev. 2009;28(1):35–49. · DOI
  187. Ren Y, et al. The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome. Proteomics. 2004;4(11):3477–84. · doi:10.1002/pmic.200400897
  188. Luan J, et al. Multiplex detection of 60 hepatitis B virus variants by maldi-tof mass spectrometry. Clin Chem. 2009;55(8):1503–9. · DOI
  189. Peng J, et al. Sensitive and rapid detection of viruses associated with hand foot and mouth disease using multiplexed MALDI-TOF analysis. J Clin Virol. 2013;56(2):170–4. · doi:10.1016/j.jcv.2012.10.020
  190. Calderaro A, et al. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry applied to virus identification. Sci Rep. 2014;4(1):1–10. · DOI
  191. Calderaro A, et al. Identification of different respiratory viruses, after a cell culture step, by matrix assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS). Sci Rep. 2016;6(1):1–13. · DOI
  192. Ihling C, et al. Mass spectrometric identification of SARS-CoV-2 proteins from gargle solution samples of COVID-19 patients. J Proteome Res. 2020;19(11):4389–92. · DOI · Paper page
  193. Yan L, et al. Rapid detection of COVID-19 using MALDI-TOF-based serum peptidome profiling. Anal Chem. 2021;93(11):4782–7. · DOI
  194. Nachtigall FM, et al. Detection of SARS-CoV-2 in nasal swabs using MALDI-MS. Nat Biotechnol. 2020;38(10):1168–73. · DOI · Paper page
  195. Roberts DS, et al. Structural O-glycoform heterogeneity of the SARS-CoV-2 spike protein receptor-binding domain revealed by top-down mass spectrometry. J Am Chem Soc. 2021;143(31):12014–24. · DOI
  196. De Silva IW, et al. Paper spray mass spectrometry utilizing Teslin® substrate for rapid detection of lipid metabolite changes during COVID-19 infection. Analyst. 2020;145(17):5725–32. · DOI
  197. Cardozo KHM, et al. Establishing a mass spectrometry-based system for rapid detection of SARS-CoV-2 in large clinical sample cohorts. Nat Commun. 2020;11(1):1–13. · DOI · Paper page
  198. Van Puyvelde B, et al. Cov-MS: a community-based template assay for mass-spectrometry-based protein detection in SARS-CoV-2 patients. Jacs Au. 2021;1(6):750–65. · DOI
  199. Van Puyvelde B et al. Cov2MS: an automated matrix-independent assay for mass spectrometric detection and measurement of SARS-CoV-2 nucleocapsid protein in infectious patients. medRxiv, 2022. · DOI
  200. Hober A, et al. Rapid and sensitive detection of SARS-CoV-2 infection using quantitative peptide enrichment LC-MS analysis. Elife. 2021;10:e70843. · doi:10.7554/elife.70843

200 of 306 shown

Cited by

See all 220

Metadata

Authors
Birhanu, A. G.
Venue
Clinical Proteomics
Published
2023-08-26
Volume
20
Issue
1
Pages
32-32
ISSN
  • 1542-6416 (ISSN-L)
  • 1559-0275
OpenAlex
W4386195889
Cited by
220
References
22
FWCI
19.31
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. https://app.cochat.ai/papers/10.1186/s12014-023-09424-x
The paper
Birhanu, A. G. (2023). Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clinical Proteomics. https://doi.org/10.1186/s12014-023-09424-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.